SEHK:1177Pharmaceuticals
Bepirovirsen Breakthrough and Naldemedine Approval Could Be A Game Changer For Sino Biopharmaceutical (SEHK:1177)
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing recently reported positive Phase III data for bepirovirsen in chronic hepatitis B and secured China NMPA approval for naldemedine to treat opioid-induced constipation in adults.
The bepirovirsen data point to materially higher functional cure rates than current lifelong therapies, highlighting Sino Biopharmaceutical’s role in advancing virus control and cancer risk reduction.
We’ll now examine how bepirovirsen’s functional cure potential...